postoperative 0.5% Ropivacaine hydrochloride — Competitive Intelligence Brief

postoperative 0.5% Ropivacaine hydrochloride (postoperative 0.5% Ropivacaine hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide). Area: Anesthesia / Pain Management.

marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

postoperative 0.5% Ropivacaine hydrochloride (postoperative 0.5% Ropivacaine hydrochloride) — China Medical University, China. Ropivacaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
postoperative 0.5% Ropivacaine hydrochloride TARGET	postoperative 0.5% Ropivacaine hydrochloride	China Medical University, China	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Isobaric bupivacaine 0.5%	Isobaric bupivacaine 0.5%	Hospital Clínico Universitario de Valencia	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
IV Lidocaine	IV Lidocaine	University of Washington	marketed	Local anesthetic / Antiarrhythmic agent (Class IB)	Voltage-gated sodium channels
Lidocaïne	Lidocaïne	University Hospital, Angers	marketed	Local anesthetic	Voltage-gated sodium channels
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Lidocaine alone	Lidocaine alone	TriHealth Inc.	marketed	Local anesthetic	Voltage-gated sodium channels
lidocaine and sufentanil	lidocaine and sufentanil	RenJi Hospital	marketed	Local anesthetic and opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide) class)

1. Poznan University of Medical Sciences · 4 drugs in this class
2. Nantes University Hospital · 3 drugs in this class
3. Bozyaka Training and Research Hospital · 2 drugs in this class
4. ASST Gaetano Pini-CTO · 2 drugs in this class
5. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
6. Chiang Mai University · 1 drug in this class
7. Beijing Tiantan Hospital · 1 drug in this class
8. Complejo Hospitalario Universitario de Granada · 1 drug in this class
9. Ciusss de L'Est de l'Île de Montréal · 1 drug in this class
10. China Medical University, China · 1 drug in this class